COEXPRESSION OF IMMUNE CHECKPOINT MARKERS PD-1, PD-L1, TIM-3, AND LAG-3 IN CIRCULATING AND TUMOR-INFILTRATING T CELL POPULATIONS IN CERVICAL CANCER PATIENTS



Cite item

Full Text

Abstract

The article presents the results of immunophenotyping performed on T cells from early-stage cervical cancer patients using immune checkpoint markers considered as promising and valid targets for antitumor immunotherapy. The differences in the expression pattern of these markers between lymphocyte subpopulations isolated from the tumor site or peripheral blood are discussed.

About the authors

O. V. Kurmyshkina

Petrozavodsk State University

Author for correspondence.
Email: fake@neicon.ru

PhD, seniorresearcher, Laboratory of Molecular Genetics of Innate Immunity, Institute of High-Tech Biomedicine,

Petrozavodsk

Russian Federation

A. A. Bogdanova

Petrozavodsk State University;
Institute of Biology of the Karelian Research Centre of the RAS

Email: fake@neicon.ru

PhD student, Laboratory for Environmental Biochemistry,

Petrozavodsk

Russian Federation

P. I. Kovchur

Petrozavodsk State University

Email: fake@neicon.ru

MD-PhD, professor of the Department of hospital surgery, ENT diseases, ophthalmology, dentistry, oncology, urology, Institute of Medicine,

Petrozavodsk

Russian Federation

T. O. Volkova

Petrozavodsk State University

Email: VolkovaTO@yandex.ru

PhD, professor of the Department ofbiomedical chemistry, immunology and laboratory diagnostics, Institute of Medicine; director of the Institute of High-Tech Biomedicine,

Petrozavodsk

Russian Federation

References

  1. Wang HF, Wang SS, Tang YJ, Chen Y, Zheng M, Tang YL, Liang XH. The Double-Edged Sword-How Human Papillomaviruses Interact With Immunity in Head and Neck Cancer.Front Immunol. 2019, 10, 653.
  2. Liu Y, Wu L, Tong R, Yang F, Yin L, Li M, You L, Xue J, Lu Y. PD-1/PD-L1 Inhibitors in Cervical Cancer.Front Pharmacol. 2019, 10, 65.
  3. Heeren AM, Rotman J, Stam AGM, Pocorni N, Gassama AA, Samuels S, Bleeker MCG, Mom CH, Zij lmans HJMAA, Kenter GG, Jordanova ES, de Gruij l TD. Efficacy of PD-1 blockade in cervical cancer is related to a CD8+FoxP3+CD25+ T-cell subset with operational effector functions despite high immune checkpoint levels. J Immunother Cancer. 2019, 7, 43.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2019 Kurmyshkina O.V., Bogdanova A.A., Kovchur P.I., Volkova T.O.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № 77 - 11525 от 04.01.2002.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies